Identifying Daytime Hypercapnia Using Transcutaneous Carbon Dioxide Monitoring in Patients With Amyotrophic Lateral...

Area of Science:

• Neurology
• Pulmonology
• Medical Diagnostics

Background:

• Respiratory failure due to hypoventilation is the primary cause of death in amyotrophic lateral sclerosis (ALS).
• Hypercapnia, a key indicator of hypoventilation, is infrequently assessed in ALS patient care.
• Transcutaneous carbon dioxide (tcCO2) monitoring offers a direct measure of hypercapnia.

Purpose of the Study:

• To determine the prevalence of daytime hypercapnia in ALS patients using tcCO2 monitoring.
• To evaluate the clinical significance of hypercapnia, including its association with survival.
• To assess the diagnostic accuracy of patient-reported symptoms and pulmonary function tests (PFTs) in detecting hypercapnia.

Main Methods:

• Retrospective analysis of 10% of ALS patients from two US clinics (2012-2024).
• Concurrent measurement of tcCO2 with PFTs, including forced vital capacity (FVC) and maximum inspiratory pressure (MIP).
• Assessment of hypercapnia prevalence (tcCO2 > 45 mmHg), symptom/PFT sensitivity and specificity, and survival impact.

Main Results:

• Daytime hypercapnia was identified in 10% (33/328) of patients at baseline.
• Hypercapnia was significantly associated with an increased mortality risk (aHR 2.1).
• High sensitivity for hypercapnia was observed for orthopnea/dyspnea (70%), absolute MIP < 60 cmH2O (95%), and FVC < 80% predicted (85%).
• High specificity for hypercapnia was noted for FVC < 50% predicted (82%).

Conclusions:

• TcCO2 monitoring effectively highlights the diagnostic utility and limitations of PFTs for identifying hypercapnia in ALS.
• Specific PFT parameters like absolute MIP < 60 cmH2O and FVC < 80% predicted show high sensitivity, while FVC < 50% predicted demonstrates high specificity for hypercapnia.
• Further prospective research is warranted to establish the optimal clinical application of tcCO2 monitoring in ALS management.